Cart
sales@molnova.com
Remetinostat
CAS No. 946150-57-8
Remetinostat( SHP-141 )
Catalog No. M24995 CAS No. 946150-57-8
Remetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 125 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 402 | In Stock |
|
| 100MG | 642 | In Stock |
|
| 200MG | 888 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRemetinostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionRemetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes.
-
DescriptionRemetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes. It is under development for the treatment of cutaneous T-cell lymphoma.
-
In Vitro——
-
In Vivo——
-
SynonymsSHP-141
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number946150-57-8
-
Formula Weight323.34
-
Molecular FormulaC16H21NO6
-
Purity>98% (HPLC)
-
SolubilityDMSO:150 mg/mL (463.91 mM; Need ultrasonic)
-
SMILESCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCCC(=O)NO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.
molnova catalog
related products
-
CAY-10603
A highly potent and selective HDAC6 inhibitor with IC50 of 2 pM.
-
4SC-202 free base
4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively.
-
CHR-3996
CHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3.
